Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study

Author(s):
Lantinga, M.A.; D'Agnolo, H.M.A.; Casteleijn, N.F.; Fijter, J.W. de; Meijer, E.; Messchendorp, A.L.; Peters, D.J.M. (0000-0001-6974-7143); Salih, M.; Spithoven, E.M.; Soonawala, D.; Visser, F.W.; Wetzels, J.F.M.; Zietse, R.; Drenth, J.P.H.; Gansevoort, R.T.; DIPAK Consortium
Published
2017
Publication type
Article / Letter to editor
Date issued
2017-02-28
Language
English
Is part of
Drug Safety (2017), Vol. 40, no. 2, p. 153-167
hdl
1887/94764
doi
10.1007/s40264-016-0486-x